A Phase 1 interventional study of PA21 and Losartan with Food and No PA21; Losartan with food in Drug Interaction Potentiation, sponsored by Vifor Pharma. Completed at 1 site in United States. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-21.
Sponsored by Vifor Pharma (part of CSL Limited) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if Losartan potassium is affected by PA21.
Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.
First submitted before Vifor Pharma became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PA21 and Losartan with Food
Drug: No PA21; Losartan with food
Drug: PA21 with food and Losartan 2 hours later
The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
The maximum dose of Losartan will be 100 mg/day.
The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Effect of PA21 on Losartan potassium
To assess the effect, if any, of PA21 on Losartan potassium exposure
Time frame: PK assessment on Day 0, 11, 22
Effect of PA21 on the active metabolite of Losartan potassium
To assess the effect, if any, of PA21 on the active metabolite of Losartan potassium
Time frame: PK assessment on Day 0, 11, 22
The record gives a start of Mar 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PA21 · Losartan